Galectin Therapeutics Inc (NASDAQ:GALT)

3.29
Delayed Data
As of Apr 24
 -0.04 / -1.20%
Today’s Change
3.00
Today|||52-Week Range
16.55
-5.19%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$77.7M

Company Description

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.

Contact Information

Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard
Norcross Georgia 30071
P:(678) 620-3186
Investor Relations:

Employees

Shareholders

Individual stakeholders9.66%
Mutual fund holders9.47%
Other institutional6.64%

Top Executives

Peter G. TraberPresident, CEO, Director & Chief Medical Officer
Harold H. ShlevinChief Operating Officer & Secretary
Jack W. CallicuttChief Financial Officer
Eliezer ZomerExecutive VP-Manufacturing & Product Development
J. Rex HortonExecutive Director-Regulatory Affairs

To view my watchlist

Not a member yet?

Sign up now for a free account